KRRO vs. CALT, PAHC, ALT, OLMA, PHAT, ATXS, AVBP, MLYS, STOK, and VERV
Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Altimmune (ALT), Olema Pharmaceuticals (OLMA), Phathom Pharmaceuticals (PHAT), Astria Therapeutics (ATXS), ArriVent BioPharma (AVBP), Mineralys Therapeutics (MLYS), Stoke Therapeutics (STOK), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Korro Bio. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Calliditas Therapeutics AB (publ) presently has a consensus target price of $34.00, suggesting a potential upside of 74.36%. Korro Bio has a consensus target price of $126.25, suggesting a potential upside of 100.62%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Calliditas Therapeutics AB (publ).
In the previous week, Korro Bio had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Korro Bio and 5 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 1.11 beat Korro Bio's score of 0.19 indicating that Korro Bio is being referred to more favorably in the news media.
Korro Bio has a net margin of 0.00% compared to Korro Bio's net margin of -38.72%. Korro Bio's return on equity of -104.47% beat Calliditas Therapeutics AB (publ)'s return on equity.
2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 16.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Calliditas Therapeutics AB (publ) received 17 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500.
Summary
Korro Bio beats Calliditas Therapeutics AB (publ) on 12 of the 18 factors compared between the two stocks.
Get Korro Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Korro Bio Competitors List
Related Companies and Tools
